P I Industries Ltd

- No specific mention of any current or planned fundraising through debt or equity in the transcript. - The company highlights a debt-free balance sheet with net cash of INR 35 billion, indicating strong liquidity and financial flexibility. - Management emphasizes strategic investments funded through existing resources. - They are actively evaluating synergistic and knowledge-led growth opportunities but have not indicated any capital raising plans. - CAPEX for FY27 is guided around INR 500-600 crore, expected to be funded through internal accruals. - Overall, no explicit plans or announcements for new debt or equity fundraising as of now.

- FY27 capex guidance is broadly INR 500 crore to INR 600 crore, with formal guidance expected post Board approval next quarter. - Plans are underway for setting up a pharma intermediate plant in India; further details to be announced soon. - Expansion from 2 to 3 multipurpose plants, with the third plant largely targeted for pharma business. - Company is actively evaluating various strategic and synergistic investment opportunities aligned with knowledge-led capabilities, both within AgChem and potentially outside it. - Focus on building differentiated plays in specialty, electronic chemicals, biologicals, and pharma segments. - Investments are seen as long-term value creation rather than short-term expenses, with expectations of future growth engines in pharma and biologicals.

- Sequential volume growth expected beginning Q4 FY26, with recovery momentum building into FY27. - FY27 is anticipated to see overall revenue growth as industry conditions stabilize and new product ramp-up progresses. - Growth in the contract research and manufacturing (CRDMO) pharma business expected to strengthen as capabilities mature, targeting EBITDA positivity once topline hits INR 400-500 crore. - Domestic agrochemical growth projected to return on track from FY27 following subdued demand in FY26 due to high channel inventory and regulatory impacts. - New product commercialization is a key driver; 5 new molecules commercialized in AgChem exports and 4 in domestic agriculture in FY26, with 8-10 new molecules expected to be commercialized soon. - Positive demand signals and stabilization in global and domestic markets underpin management's confidence for mid to high single-digit growth over FY27.

- Q4 FY26 expected to show sequential volume growth, with initial signs of recovery beginning. - FY27 anticipated to see growth momentum building with gradual recovery after industry stabilization. - Earnings growth expected to be positive in FY27, supported by new product ramp-up and improving market conditions. - EBITDA margin may face short-term pressure due to investments, but strong gross margins (around 50-52%) are targeted sustainably. - New product portfolio continues to grow (~10% growth in new products for 9 months FY26), supporting de-risking strategy. - Biologicals contributing around 20% of revenue and expected to drive long-term growth with scalable global franchise. - Operating profits may be impacted short term by investments, but medium-term outlook remains positive with technology and partnership-driven growth. - Order book remains strong (~$1.2 billion), supporting sustained revenue and profit growth prospects.

- As of the quarter ending December 31, 2025, the order book stands at approximately $1.2 billion. - The company regularly shares updates on the order book and this figure was confirmed during the earnings call. - No indication of a decline in the order book was mentioned; relationships with large European and American customers continue to add new products and evaluations. - The $1.2 billion order book reflects a healthy pipeline supporting the company’s contract manufacturing services (CSM) and other businesses. - The company expects growth momentum to build from Q4 FY26 and into FY27 as industry conditions stabilize and new product commercialization progresses.